Signadori Bio SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Signadori Bio SAS - overview
Established
2025
Location
Paris, -, France
Primary Industry
Biotechnology
About
Established in 2025, and based in Paris, France, Signadori Bio operates as a biotechnology research company that offer its clients a preclinical stage biopharmaceutical company developing a next generation in vivo monocyte immunotherapy to treat solid tumors.
Current Investors
Sofinnova Partners, Taiho Ventures, Invivo Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Oncology/Cancer Treatment
Website
www.signadoribio.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.